Literature DB >> 17846508

Marked expansion of CD11c+CD8+ T-cells in melanoma-bearing mice induced by anti-4-1BB monoclonal antibody.

Seong-A Ju1, Sang-Min Park, Sang-Chul Lee, Byoung S Kwon, Byung-Sam Kim.   

Abstract

4-1BB (CD137), a member of the tumor necrosis factor receptor superfamily, is expressed on activated T-cells, and 4-1BB signaling due to interaction with 4-1BB ligand or ligation with anti-4-1BB monoclonal antibody (mAb) costimulates T cells. It has been shown that administration of anti-4-1BB mAb induces anti-tumor immunity in mice, but the nature of the cellular subsets responsible for this immunity is uncertain. In this study we found that anti-4-1BB mAb administration to B16F10 melanoma-bearing mice induced marked expansion of CD11c+CD8+ T-cells in parallel with suppression of pulmonary tumors. The mAb-treated mice produced higher levels of IFN- in their tumor tissues, spleen and lymph nodes than mice exposed to control antibody. When the CD11c+CD8+ T-cells were purified and re-stimulated in vitro, they produced high levels of the Th1 cytokines, IFN- and IL-2, but low levels of the Th2 cytokines, IL-4 and IL-10. Furthermore, they expressed high levels of 4-1BB and CD107a, a marker of activated cytotoxic T-lymphocytes. Our results suggest that CD11c+CD8+ T-cells play a role in the anti-tumor immunity induced by anti-4-1BB mAb.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17846508

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  8 in total

Review 1.  SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Authors:  Rajesh K Sharma; Esma S Yolcu; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2014-03       Impact factor: 5.217

2.  Short-lived effector CD8 T cells induced by genetically attenuated malaria parasite vaccination express CD11c.

Authors:  Laura A Cooney; Megha Gupta; Sunil Thomas; Sebastian Mikolajczak; Kimberly Y Choi; Claire Gibson; Ihn K Jang; Sam Danziger; John Aitchison; Malcolm J Gardner; Stefan H I Kappe; Ruobing Wang
Journal:  Infect Immun       Date:  2013-08-26       Impact factor: 3.441

Review 3.  Immune regulation and control of regulatory T cells by OX40 and 4-1BB.

Authors:  Takanori So; Seung-Woo Lee; Michael Croft
Journal:  Cytokine Growth Factor Rev       Date:  2008-05-27       Impact factor: 7.638

4.  Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin.

Authors:  Michael A Curran; Theresa L Geiger; Welby Montalvo; Myoungjoo Kim; Steven L Reiner; Aymen Al-Shamkhani; Joseph C Sun; James P Allison
Journal:  J Exp Med       Date:  2013-04-01       Impact factor: 14.307

Review 5.  4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity.

Authors:  Todd Bartkowiak; Michael A Curran
Journal:  Front Oncol       Date:  2015-06-08       Impact factor: 6.244

6.  B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+ tumor-infiltrating lymphocytes.

Authors:  Gihoon You; Yangsoon Lee; Yeon-Woo Kang; Han Wook Park; Kyeongsu Park; Hyekang Kim; Young-Min Kim; Sora Kim; Ji-Hae Kim; Dain Moon; Hyejin Chung; Wonjun Son; Ui-Jung Jung; Eunyoung Park; Shinai Lee; Yong-Gyu Son; Jaehyun Eom; Jonghwa Won; Yunji Park; Jaeho Jung; Seung-Woo Lee
Journal:  Sci Adv       Date:  2021-01-15       Impact factor: 14.136

7.  Anti-4-1BB antibody-based combination therapy augments antitumor immunity by enhancing CD11c+CD8+ T cells in renal cell carcinoma.

Authors:  Seong-A Ju; Sang-Min Park; Yeonsoo Joe; Hun Taeg Chung; Won G An; Byung-Sam Kim
Journal:  Oncol Lett       Date:  2021-12-06       Impact factor: 2.967

8.  Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8(+) T cells during vaccine immunotherapy.

Authors:  Yohei Takeda; Masahiro Azuma; Misako Matsumoto; Tsukasa Seya
Journal:  J Exp Clin Cancer Res       Date:  2016-09-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.